{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T10:07:39Z","timestamp":1774433259771,"version":"3.50.1"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100001212","name":"Koret Foundation","doi-asserted-by":"publisher","award":["Digital Living 2030"],"award-info":[{"award-number":["Digital Living 2030"]}],"id":[{"id":"10.13039\/100001212","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Care Manag Sci"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s10729-022-09607-2","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T07:10:28Z","timestamp":1661325028000},"page":"725-749","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Country versus pharmaceutical company interests for hepatitis C treatment"],"prefix":"10.1007","volume":"25","author":[{"given":"Roy","family":"Lothan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noa","family":"Gutman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1131-5572","authenticated-orcid":false,"given":"Dan","family":"Yamin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"key":"9607_CR1","unstructured":"World Health Organization (2018) Hepatitis C. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c"},{"key":"9607_CR2","unstructured":"World Health Organization (2017) Global Hepatitis Report, 2017"},{"key":"9607_CR3","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1002\/hep.26141","volume":"5","author":"K Mohd Hanafiah","year":"2013","unstructured":"Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST (2013) Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology 5:1333\u20131342. https:\/\/doi.org\/10.1002\/hep.26141","journal-title":"Hepatology"},{"key":"9607_CR4","doi-asserted-by":"publisher","first-page":"7824","DOI":"10.3748\/wjg.v22.i34.7824","volume":"22","author":"A Petruzziello","year":"2016","unstructured":"Petruzziello A, Marigliano S, Loquercio G et al (2016) Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol 22:7824\u20137840. https:\/\/doi.org\/10.3748\/wjg.v22.i34.7824","journal-title":"World J Gastroenterol"},{"key":"9607_CR5","unstructured":"Centers for Disease Control and Prevention (2016) Hepatitis C Kills More Americans than Any Other Infectious Disease"},{"key":"9607_CR6","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1136\/gut.2005.078147","volume":"55","author":"I Bakr","year":"2006","unstructured":"Bakr I, Rekacewicz C, El Hosseiny M et al (2006) Higher clearance of hepatitis C virus infection in females compared with males. Gut 55:1183\u20131187. https:\/\/doi.org\/10.1136\/gut.2005.078147","journal-title":"Gut"},{"key":"9607_CR7","doi-asserted-by":"crossref","unstructured":"Hoofnagle JH (2002) Course and outcome of hepatitis C. In: Hepatology. pp s21\u2013s29","DOI":"10.1053\/jhep.2002.36227"},{"key":"9607_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1177\/00333549071220s211","volume":"122","author":"AA Honeycutt","year":"2007","unstructured":"Honeycutt AA, Harris JL, Khavjou O et al (2007) The costs and impacts of testing for hepatitis C virus antibody in public STD clinics. Public Health Rep 122:55\u201362. https:\/\/doi.org\/10.1177\/00333549071220s211","journal-title":"Public Health Rep"},{"key":"9607_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.7150\/ijms.3.47","volume":"3","author":"SL Chen","year":"2006","unstructured":"Chen SL, Morgan TR (2006) The natural history of hepatitis C virus (HCV) Infection. Int J Med Sci 3:47\u201352. https:\/\/doi.org\/10.7150\/ijms.3.47","journal-title":"Int J Med Sci"},{"key":"9607_CR10","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","volume":"349","author":"T Poynard","year":"1997","unstructured":"Poynard T, Bedossa P, Opolon P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 349:825\u2013832. https:\/\/doi.org\/10.1016\/S0140-6736(96)07642-8","journal-title":"Lancet"},{"key":"9607_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026783","volume":"6","author":"S Liu","year":"2011","unstructured":"Liu S, Schwarzinger M, Carrat F, Goldhaber-Fiebert JD (2011) Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients. PLoS ONE 6:e26783. https:\/\/doi.org\/10.1371\/journal.pone.0026783","journal-title":"PLoS ONE"},{"key":"9607_CR12","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.jval.2013.07.005","volume":"16","author":"M Ruggeri","year":"2013","unstructured":"Ruggeri M, Coretti S, Gasbarrini A, Cicchetti A (2013) Economic assessment of an anti-HCV screening program in Italy. Value Heal 16:965\u2013972. https:\/\/doi.org\/10.1016\/j.jval.2013.07.005","journal-title":"Value Heal"},{"key":"9607_CR13","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","volume":"5","author":"L Degenhardt","year":"2017","unstructured":"Degenhardt L, Peacock A, Colledge S et al (2017) Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Heal 5:e1192\u2013e1207. https:\/\/doi.org\/10.1016\/S2214-109X(17)30375-3","journal-title":"Lancet Glob Heal"},{"key":"9607_CR14","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S1473-3099(16)30325-5","volume":"16","author":"L Degenhardt","year":"2016","unstructured":"Degenhardt L, Charlson F, Stanaway J et al (2016) Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. Lancet Infect Dis 16:1385\u20131398. https:\/\/doi.org\/10.1016\/S1473-3099(16)30325-5","journal-title":"Lancet Infect Dis"},{"key":"9607_CR15","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1186\/s12879-019-4284-9","volume":"19","author":"R Han","year":"2019","unstructured":"Han R, Zhou J, Fran\u00e7ois C, Toumi M (2019) Prevalence of hepatitis C infection among the general population and high-risk groups in the EU\/EEA: a systematic review update. BMC Infect Dis 19:655. https:\/\/doi.org\/10.1186\/s12879-019-4284-9","journal-title":"BMC Infect Dis"},{"key":"9607_CR16","unstructured":"FDA (2018) Hepatitis B and C Treatments. https:\/\/www.fda.gov\/patients\/hepatitis-b-c\/hepatitis-b-and-c-treatments"},{"key":"9607_CR17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jamainternmed.2015.6011","volume":"176","author":"HS Chahal","year":"2016","unstructured":"Chahal HS, Marseille EA, Tice JA et al (2016) Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population. JAMA Intern Med 176:65\u201373. https:\/\/doi.org\/10.1001\/jamainternmed.2015.6011","journal-title":"JAMA Intern Med"},{"key":"9607_CR18","unstructured":"World Health Organization (2016) Global Health Sector Strategy on Viral Hepatitis, 2016 \u2013 2021. In: World Heal. Organ. https:\/\/www.who.int\/hepatitis\/strategy2016-2021\/ghss-hep\/en\/"},{"key":"9607_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/S41575-020-00392-3","volume":"18","author":"GJ Dore","year":"2021","unstructured":"Dore GJ, Bajis S (2021) Hepatitis C virus elimination: laying the foundation for achieving 2030 targets. Nat Rev Gastroenterol Hepatol 18:91\u201392. https:\/\/doi.org\/10.1038\/S41575-020-00392-3","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"9607_CR20","doi-asserted-by":"publisher","unstructured":"Iyengar S, Tay-Teo K, Vogler S et al (2016) Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: An economic analysis. PLOS Med 13. https:\/\/doi.org\/10.1371\/journal.pmed.1002032","DOI":"10.1371\/journal.pmed.1002032"},{"key":"9607_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jve.2020.06.001","author":"MJ Barber","year":"2019","unstructured":"Barber MJ, Gotham D, Khwairakpam G, Hill A (2019) Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries. J Virus Erad. https:\/\/doi.org\/10.1016\/j.jve.2020.06.001","journal-title":"J Virus Erad"},{"key":"9607_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13027-016-0071-z","volume":"11","author":"ES Rosenthal","year":"2016","unstructured":"Rosenthal ES, Graham CS (2016) Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States. Infect Agent Cancer 11:24","journal-title":"Infect Agent Cancer"},{"key":"9607_CR23","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/liv.12066","volume":"33","author":"ML Shiffman","year":"2013","unstructured":"Shiffman ML, Benhamou Y (2013) Patients with HCV and F1 and F2 fibrosis stage: treat now or wait? Liver Int 33:105\u2013110. https:\/\/doi.org\/10.1111\/liv.12066","journal-title":"Liver Int"},{"key":"9607_CR24","doi-asserted-by":"publisher","first-page":"397","DOI":"10.7326\/M14-1336","volume":"162","author":"J Chhatwal","year":"2015","unstructured":"Chhatwal J, Kanwal F, Roberts MS, Dunn MA (2015) Cost-effectiveness and budget impact of hepatitis C virus treatment with Sofosbuvir and Ledipasvir in the United States. Ann Intern Med 162:397. https:\/\/doi.org\/10.7326\/M14-1336","journal-title":"Ann Intern Med"},{"key":"9607_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/cid\/civ220","volume":"61","author":"DB Rein","year":"2015","unstructured":"Rein DB, Wittenborn JS, Smith BD et al (2015) The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. Clin Infect Dis 61:157\u2013168. https:\/\/doi.org\/10.1093\/cid\/civ220","journal-title":"Clin Infect Dis"},{"key":"9607_CR26","doi-asserted-by":"crossref","unstructured":"Coward S, Leggett L, Kaplan GG, Clement F (2016) Cost-effectiveness of screening for hepatitis C virus: A systematic review of economic evaluations. BMJ Open 6","DOI":"10.1136\/bmjopen-2016-011821"},{"key":"9607_CR27","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/cid\/civ894","volume":"62","author":"DP Durham","year":"2016","unstructured":"Durham DP, Skrip LA, Bruce RD et al (2016) The impact of enhanced screening and treatment on hepatitis C in the United States. Clin Infect Dis 62:298\u2013304. https:\/\/doi.org\/10.1093\/cid\/civ894","journal-title":"Clin Infect Dis"},{"key":"9607_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/jvh.12351","volume":"22","author":"A Hatzakis","year":"2015","unstructured":"Hatzakis A, Chulanov V, Gadano AC et al (2015) The present and future disease burden of hepatitis C virus (HCV) infections with today\u2019s treatment paradigm - volume 2. J Viral Hepat 22:26\u201345. https:\/\/doi.org\/10.1111\/jvh.12351","journal-title":"J Viral Hepat"},{"key":"9607_CR29","doi-asserted-by":"publisher","first-page":"e440","DOI":"10.1016\/S2214-109X(20)30003-6","volume":"8","author":"AG Lim","year":"2020","unstructured":"Lim AG, Walker JG, Mafirakureva N et al (2020) Effects and cost of different strategies to eliminate hepatitis C virus transmission in Pakistan: a modelling analysis. Lancet Glob Heal 8:e440\u2013e450. https:\/\/doi.org\/10.1016\/S2214-109X(20)30003-6","journal-title":"Lancet Glob Heal"},{"key":"9607_CR30","unstructured":"Willison D, Wiktorowicz M, Grootendorst P et al (2001) International Experience with Pharmaceutical Policy: Common Challenges and Lessons for Canada. Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada"},{"key":"9607_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3138\/canlivj.1.2.003","volume":"1","author":"SB H\u00f8j","year":"2018","unstructured":"H\u00f8j SB, Minoyan N, Artenie AA et al (2018) The role of prevention strategies in achieving HCV elimination in Canada: what are the remaining challenges? Can Liver J 1:4\u201313. https:\/\/doi.org\/10.3138\/canlivj.1.2.003","journal-title":"Can Liver J"},{"key":"9607_CR32","doi-asserted-by":"crossref","unstructured":"Gon\u00e7alves FR, Santos S, Silva C, Sousa G (2018) Risk-sharing agreements, present and future. Ecancermedicalscience 12","DOI":"10.3332\/ecancer.2018.823"},{"key":"9607_CR33","first-page":"1028","volume":"23","author":"JS Yu","year":"2017","unstructured":"Yu JS, Chin L, Oh J, Farias J (2017) Performance-based risk-sharing arrangements for pharmaceutical products in the United States: A systematic review. J Manag Care Spec Pharm 23:1028\u20131040","journal-title":"J Manag Care Spec Pharm"},{"key":"9607_CR34","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s41669-017-0044-1","volume":"2","author":"TJ Piatkiewicz","year":"2018","unstructured":"Piatkiewicz TJ, Traulsen JM, Holm-Larsen T (2018) Risk-sharing agreements in the EU: A systematic review of major trends. PharmacoEconomics - Open 2:109\u2013123. https:\/\/doi.org\/10.1007\/s41669-017-0044-1","journal-title":"PharmacoEconomics - Open"},{"key":"9607_CR35","unstructured":"Ramirez O (2019) Program Offers Hepatitis C Screening for Patients in UK Emergency Department"},{"key":"9607_CR36","unstructured":"Schlote W (2019) Hep C program offers cash for a cure in vulnerable populations"},{"key":"9607_CR37","volume-title":"Game Theory","author":"D Fudenberg","year":"1991","unstructured":"Fudenberg D, Tirole J (1991) Game Theory. MIT Press"},{"key":"9607_CR38","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.socscimed.2015.04.023","volume":"135","author":"SV Ramani","year":"2015","unstructured":"Ramani SV, Urias E (2015) Access to critical medicines: When are compulsory licenses effective in price negotiations? Soc Sci Med 135:75\u201383. https:\/\/doi.org\/10.1016\/j.socscimed.2015.04.023","journal-title":"Soc Sci Med"},{"key":"9607_CR39","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.2307\/23443875","volume":"59","author":"H Mamani","year":"2013","unstructured":"Mamani H, Chick SE, Simchi-Levi D (2013) A game-theoretic model of international influenza vaccination coordination. Manage Sci 59:1650\u20131670. https:\/\/doi.org\/10.2307\/23443875","journal-title":"Manage Sci"},{"key":"9607_CR40","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1287\/ijoc.2017.0786","volume":"30","author":"OY \u00d6zaltin","year":"2018","unstructured":"\u00d6zaltin OY, Prokopyev OA, Schaefer AJ (2018) Optimal design of the seasonal influenza vaccine with manufacturing autonomy. INFORMS J Comput 30:371\u2013387. https:\/\/doi.org\/10.1287\/ijoc.2017.0786","journal-title":"INFORMS J Comput"},{"key":"9607_CR41","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1287\/opre.2016.1552","volume":"65","author":"SE Chick","year":"2017","unstructured":"Chick SE, Hasija S, Nasiry J (2017) Information elicitation and influenza vaccine production. Oper Res 65:75\u201396. https:\/\/doi.org\/10.1287\/opre.2016.1552","journal-title":"Oper Res"},{"key":"9607_CR42","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1287\/mnsc.2013.1725","volume":"59","author":"D Yamin","year":"2013","unstructured":"Yamin D, Gavious A (2013) Incentives\u2019 effect in influenza vaccination policy. Manage Sci 59:2667\u20132686. https:\/\/doi.org\/10.1287\/mnsc.2013.1725","journal-title":"Manage Sci"},{"key":"9607_CR43","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10198-013-0544-6","volume":"15","author":"A Gavious","year":"2014","unstructured":"Gavious A, Greenberg D, Hammerman A, Segev E (2014) Impact of a financial risk-sharing scheme on budget-impact estimations: a game-theoretic approach. Eur J Heal Econ 15:553\u2013561. https:\/\/doi.org\/10.1007\/s10198-013-0544-6","journal-title":"Eur J Heal Econ"},{"key":"9607_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/hec.3903","author":"GJ Critchley","year":"2019","unstructured":"Critchley GJ, Zaric GS (2019) The impact of pharmaceutical marketing on market access, treatment coverage, pricing, and social welfare. Heal Econ (United Kingdom). https:\/\/doi.org\/10.1002\/hec.3903","journal-title":"Heal Econ (United Kingdom)"},{"key":"9607_CR45","doi-asserted-by":"publisher","DOI":"10.1287\/mnsc.2019.3574","author":"E Adida","year":"2021","unstructured":"Adida E (2021) Outcome-based pricing for new pharmaceuticals via rebates. Manage Sci. https:\/\/doi.org\/10.1287\/mnsc.2019.3574","journal-title":"Manage Sci"},{"key":"9607_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1603","author":"PP Barros","year":"2011","unstructured":"Barros PP (2011) The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry. Health Econ. https:\/\/doi.org\/10.1002\/hec.1603","journal-title":"Health Econ"},{"key":"9607_CR47","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1287\/opre.1080.0527","volume":"56","author":"SE Chick","year":"2008","unstructured":"Chick SE, Mamani H, Simchi-Levi D (2008) Supply chain coordination and influenza vaccination. Oper Res 56:1493. https:\/\/doi.org\/10.1287\/opre.1080.0527","journal-title":"Oper Res"},{"key":"9607_CR48","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3390\/math6100190","volume":"6","author":"A Di Liddo","year":"2018","unstructured":"Di Liddo A (2018) Price and treatment decisions in epidemics: a differential game approach. Mathematics 6:190. https:\/\/doi.org\/10.3390\/math6100190","journal-title":"Mathematics"},{"key":"9607_CR49","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"J-M Pawlotsky","year":"2018","unstructured":"Pawlotsky J-M, Negro F, Aghemo A et al (2018) EASL recommendations on treatment of hepatitis C 2018. J Hepatol 69:461\u2013511. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.026","journal-title":"J Hepatol"},{"key":"9607_CR50","unstructured":"Smith BD, Morgan RL, Beckett GA et al (2012) Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945\u20131965. MMWR Recomm reports Morb Mortal Wkly report Recomm reports"},{"key":"9607_CR51","doi-asserted-by":"publisher","unstructured":"World Health Organization (2003) Making Choices in Health: WHO Guide to Cost-effectiveness Analysis. https:\/\/doi.org\/10.1007\/1-4020-2127-5_16","DOI":"10.1007\/1-4020-2127-5_16"},{"issue":"4","key":"9607_CR52","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/BF01766400","volume":"41","author":"R Selten","year":"1975","unstructured":"Selten R (1975) (1975) Reexamination of the perfectness concept for equilibrium points in extensive games. Int J Game Theory 41(4):25\u201355. https:\/\/doi.org\/10.1007\/BF01766400","journal-title":"Int J Game Theory"},{"key":"9607_CR53","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/0022-0531(83)90076-5","volume":"31","author":"D Fudenberg","year":"1983","unstructured":"Fudenberg D, Levine D (1983) Subgame-perfect equilibria of finite- and infinite-horizon games. J Econ Theory 31:251\u2013268. https:\/\/doi.org\/10.1016\/0022-0531(83)90076-5","journal-title":"J Econ Theory"},{"key":"9607_CR54","doi-asserted-by":"publisher","first-page":"613","DOI":"10.2307\/1911658","volume":"53","author":"C Harris","year":"1985","unstructured":"Harris C (1985) Existence and characterization of perfect equilibrium in games of perfect information. Econometrica 53:613. https:\/\/doi.org\/10.2307\/1911658","journal-title":"Econometrica"},{"key":"9607_CR55","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1053\/j.gastro.2018.01.005","volume":"154","author":"M Thiele","year":"2018","unstructured":"Thiele M, Madsen BS, Hansen JF et al (2018) Accuracy of the enhanced liver fibrosis test vs fibrotest, elastography, and indirect markers in detection of advanced fibrosis in patients with alcoholic liver disease. Gastroenterology 154:1369\u20131379. https:\/\/doi.org\/10.1053\/j.gastro.2018.01.005","journal-title":"Gastroenterology"},{"key":"9607_CR56","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1053\/jhep.2001.25885","volume":"34","author":"L Yeung","year":"2001","unstructured":"Yeung L, King SM, Roberts EA (2001) Mother-to-infant transmission of hepatitis C virus. Hepatology 34:223\u2013229. https:\/\/doi.org\/10.1053\/jhep.2001.25885","journal-title":"Hepatology"},{"key":"9607_CR57","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1002\/jmv.24426","volume":"88","author":"C Weil","year":"2016","unstructured":"Weil C, Nwankwo C, Friedman M et al (2016) Epidemiology of hepatitis C virus infection in a large Israeli health maintenance organization. J Med Virol 88:1044\u20131050. https:\/\/doi.org\/10.1002\/jmv.24426","journal-title":"J Med Virol"},{"key":"9607_CR58","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jhep.2013.05.015","volume":"59","author":"T Poynard","year":"2013","unstructured":"Poynard T, Moussalli J, Munteanu M et al (2013) Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol 59:675\u2013683. https:\/\/doi.org\/10.1016\/j.jhep.2013.05.015","journal-title":"J Hepatol"},{"key":"9607_CR59","doi-asserted-by":"publisher","unstructured":"Cipriano LE, Zaric GS, Holodniy M et al (2012) Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users. PLoS ONE 7. https:\/\/doi.org\/10.1371\/journal.pone.0045176","DOI":"10.1371\/journal.pone.0045176"},{"key":"9607_CR60","doi-asserted-by":"publisher","unstructured":"Gountas I, Sypsa V, Blach S, et al (2018) HCV elimination among people who inject drugs. Modelling pre- and post\u2013WHO elimination era. PLoS One. https:\/\/doi.org\/10.1371\/journal.pone.0202109","DOI":"10.1371\/journal.pone.0202109"},{"key":"9607_CR61","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jhep.2017.10.010","volume":"68","author":"H Fraser","year":"2018","unstructured":"Fraser H, Martin NK, Brummer-Korvenkontio H et al (2018) Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. J Hepatol 68:402\u2013411. https:\/\/doi.org\/10.1016\/j.jhep.2017.10.010","journal-title":"J Hepatol"},{"key":"9607_CR62","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/J.EPIDEM.2019.02.003","volume":"27","author":"RE Gicquelais","year":"2019","unstructured":"Gicquelais RE, Foxman B, Coyle J, Eisenberg MC (2019) Hepatitis C transmission in young people who inject drugs: Insights using a dynamic model informed by state public health surveillance. Epidemics 27:86\u201395. https:\/\/doi.org\/10.1016\/J.EPIDEM.2019.02.003","journal-title":"Epidemics"},{"key":"9607_CR63","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/j.1360-0443.2007.01761.x","volume":"102","author":"AL Ball","year":"2007","unstructured":"Ball AL (2007) HIV, injecting drug use and harm reduction: a public health response. Addiction 102:684\u2013690. https:\/\/doi.org\/10.1111\/j.1360-0443.2007.01761.x","journal-title":"Addiction"},{"key":"9607_CR64","unstructured":"(2002) Management of Hepatitis C. In: NIH consensus and state-of-the-science statements. pp 1\u201346"},{"key":"9607_CR65","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1086\/425361","volume":"39","author":"M Backmund","year":"2004","unstructured":"Backmund M, Meyer K, Edlin BR (2004) Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 39:1540\u20131543. https:\/\/doi.org\/10.1086\/425361","journal-title":"Clin Infect Dis"},{"key":"9607_CR66","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1287\/opre.43.4.558","volume":"43","author":"EH Kaplan","year":"1995","unstructured":"Kaplan EH (1995) Probability models of needle exchange. Oper Res 43:558\u2013569. https:\/\/doi.org\/10.1287\/opre.43.4.558","journal-title":"Oper Res"},{"key":"9607_CR67","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780131923","author":"EH Kaplan","year":"1994","unstructured":"Kaplan EH (1994) A method for evaluating needle exchange programmes. Stat Med. https:\/\/doi.org\/10.1002\/sim.4780131923","journal-title":"Stat Med"},{"key":"9607_CR68","unstructured":"Lothan R (2020) HCV_Game_Theory. In: GitHub Repos. https:\/\/bit.ly\/310rVDI"},{"key":"9607_CR69","unstructured":"United Nations Office on Drugs and Crime (2019) World Drug Report 2019"},{"key":"9607_CR70","unstructured":"Inbar A (2015) The medical treatment of drug addiction in Israel"},{"key":"9607_CR71","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/jvh.12248","volume":"21","author":"H Razavi","year":"2014","unstructured":"Razavi H, Waked I, Sarrazin C et al (2014) The present and future disease burden of hepatitis C virus (HCV) infection with today\u2019s treatment paradigm. J Viral Hepat 21:34\u201359. https:\/\/doi.org\/10.1111\/jvh.12248","journal-title":"J Viral Hepat"},{"key":"9607_CR72","unstructured":"Knesset Israel (2014) Labor, Welfare and Health Committee - Protocol 331"},{"key":"9607_CR73","unstructured":"Florentin I, Gorbatov RP h. (2013) Severely distressed adults in crisis situations"},{"key":"9607_CR74","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","volume":"378","author":"PK Nelson","year":"2011","unstructured":"Nelson PK, Mathers BM, Cowie B et al (2011) Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. Lancet 378:571\u2013583. https:\/\/doi.org\/10.1016\/S0140-6736(11)61097-0","journal-title":"Lancet"},{"key":"9607_CR75","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1093\/cid\/ciw580","volume":"63","author":"J Grebely","year":"2016","unstructured":"Grebely J, Mauss S, Brown A et al (2016) Efficacy and safety of ledipasvir\/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of phase 3 ION trials. Clin Infect Dis 63:1405\u20131411. https:\/\/doi.org\/10.1093\/cid\/ciw580","journal-title":"Clin Infect Dis"},{"key":"9607_CR76","doi-asserted-by":"publisher","unstructured":"Grebely J, Feld JJ, Wyles D et al (2018) Sofosbuvir-based direct-acting antiviral therapies for HCV in people receiving opioid substitution therapy: An analysis of phase 3 studies. Open Forum Infect Dis 5. https:\/\/doi.org\/10.1093\/ofid\/ofy001","DOI":"10.1093\/ofid\/ofy001"},{"key":"9607_CR77","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1478-3231.2011.02535.x","volume":"31","author":"D Kershenobich","year":"2011","unstructured":"Kershenobich D, Razavi HA, Cooper CL et al (2011) Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data. Liver Int 31:4\u201317. https:\/\/doi.org\/10.1111\/j.1478-3231.2011.02535.x","journal-title":"Liver Int"},{"key":"9607_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.05.015","author":"D Yamin","year":"2014","unstructured":"Yamin D, Balicer RD, Galvani AP (2014) Cost-effectiveness of influenza vaccination in prior pneumonia patients in Israel. Vaccine. https:\/\/doi.org\/10.1016\/j.vaccine.2014.05.015","journal-title":"Vaccine"},{"key":"9607_CR79","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.893797","author":"CA Holt","year":"2002","unstructured":"Holt CA, Laury S (2002) Risk aversion and incentive effects. SSRN Electron J. https:\/\/doi.org\/10.2139\/ssrn.893797","journal-title":"SSRN Electron J"},{"key":"9607_CR80","doi-asserted-by":"publisher","unstructured":"Polaris Observatory HCV Collaborators (2017) Global prevalence and genotype distribution of hepatitis C virus infection in 2015\u202f: a modelling study. 161\u2013176. https:\/\/doi.org\/10.1016\/S2468-1253(16)30181-9","DOI":"10.1016\/S2468-1253(16)30181-9"},{"key":"9607_CR81","unstructured":"CDA Foundation Polaris Observatory. https:\/\/cdafound.org\/polaris\/"},{"key":"9607_CR82","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0157832","volume":"11","author":"Y Maor","year":"2016","unstructured":"Maor Y, Malnick SDH, Melzer E, Leshno M (2016) Treatment of chronic hepatitis C in the aged \u2013 does it impact life expectancy? A Decision Analysis PLoS One 11:e0157832. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0157832","journal-title":"A Decision Analysis PLoS One"},{"key":"9607_CR83","unstructured":"World Health Organization (2001) Considerations in evaluating the cost effectiveness of environmental health interventions"},{"key":"9607_CR84","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13584-017-0195-7","volume":"7","author":"R Nissanholtz-Gannot","year":"2018","unstructured":"Nissanholtz-Gannot R, Chinitz D (2018) Expensive lifesaving treatments: Allocating resources and maximizing access. Isr J Health Policy Res 7:3","journal-title":"Isr J Health Policy Res"},{"key":"9607_CR85","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.3109\/10826084.2016.1161054","volume":"51","author":"AK Asher","year":"2016","unstructured":"Asher AK, Portillo CJ, Cooper BA et al (2016) Clinicians\u2019 views of hepatitis C virus treatment candidacy with direct-acting antiviral regimens for people who inject drugs. Subst Use Misuse 51:1218\u20131223. https:\/\/doi.org\/10.3109\/10826084.2016.1161054","journal-title":"Subst Use Misuse"},{"key":"9607_CR86","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/jvh.12859","volume":"25","author":"O Falade-Nwulia","year":"2018","unstructured":"Falade-Nwulia O, Sulkowski MS, Merkow A et al (2018) Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era. J Viral Hepat 25:220\u2013227","journal-title":"J Viral Hepat"},{"key":"9607_CR87","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/nrgastro.2015.36","volume":"12","author":"EB Cunningham","year":"2015","unstructured":"Cunningham EB, Applegate TL, Lloyd AR et al (2015) Mixed HCV infection and reinfection in people who inject drugs-impact on therapy. Nat Rev Gastroenterol Hepatol 12:218\u2013230","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"9607_CR88","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.mbs.2016.01.003","volume":"273","author":"R Fu","year":"2016","unstructured":"Fu R, Gutfraind A, Brandeau ML (2016) Modeling a dynamic bi-layer contact network of injection drug users and the spread of blood-borne infections. Math Biosci 273:102\u2013113. https:\/\/doi.org\/10.1016\/j.mbs.2016.01.003","journal-title":"Math Biosci"},{"key":"9607_CR89","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jtbi.2011.12.008","volume":"297","author":"DA Rolls","year":"2012","unstructured":"Rolls DA, Daraganova G, Sacks-Davis R et al (2012) Modelling hepatitis C transmission over a social network of injecting drug users. J Theor Biol 297:73\u201387. https:\/\/doi.org\/10.1016\/j.jtbi.2011.12.008","journal-title":"J Theor Biol"},{"key":"9607_CR90","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1478-3231.2011.02539.x","volume":"31","author":"M Cornberg","year":"2011","unstructured":"Cornberg M, Razavi HA, Alberti A et al (2011) A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 31:30\u201360. https:\/\/doi.org\/10.1111\/j.1478-3231.2011.02539.x","journal-title":"Liver Int"},{"key":"9607_CR91","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S2468-1253(21)00472-6","volume":"7","author":"S Blach","year":"2022","unstructured":"Blach S, Terrault NA, Tacke F et al (2022) Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol 7:396\u2013415. https:\/\/doi.org\/10.1016\/S2468-1253(21)00472-6","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"9607_CR92","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s10729-015-9330-6","volume":"20","author":"S Liu","year":"2017","unstructured":"Liu S, Brandeau ML, Goldhaber-Fiebert JD (2017) Optimizing patient treatment decisions in an era of rapid technological advances: the case of hepatitis C treatment. Health Care Manag Sci 20:16\u201332. https:\/\/doi.org\/10.1007\/s10729-015-9330-6","journal-title":"Health Care Manag Sci"},{"key":"9607_CR93","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/J.JVAL.2012.01.007","volume":"15","author":"A Hammerman","year":"2012","unstructured":"Hammerman A, Feder-Bubis P, Greenberg D (2012) Financial risk-sharing in updating the national list of health services in Israel: stakeholders\u2019 perceived interests. Value Heal 15:737\u2013742. https:\/\/doi.org\/10.1016\/J.JVAL.2012.01.007","journal-title":"Value Heal"},{"key":"9607_CR94","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1377\/hlthaff.2010.1147","volume":"30","author":"PJ Neumann","year":"2011","unstructured":"Neumann PJ, Chambers JD, Simon F, Meckley LM (2011) Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement. Health Aff 30:2329\u20132337. https:\/\/doi.org\/10.1377\/hlthaff.2010.1147","journal-title":"Health Aff"},{"key":"9607_CR95","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1086\/497701","volume":"192","author":"EE Mast","year":"2005","unstructured":"Mast EE, Hwang L, Seto DSY et al (2005) Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis 192:1880\u20131889. https:\/\/doi.org\/10.1086\/497701","journal-title":"J Infect Dis"},{"key":"9607_CR96","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1046\/j.1537-2995.1994.34694295059.x","volume":"34","author":"EC Vamvakas","year":"1994","unstructured":"Vamvakas EC, Taswell HF (1994) Epidemiology of blood transfusion. Transfusion 34:464\u2013470","journal-title":"Transfusion"},{"key":"9607_CR97","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1177\/0272989X8300300403","volume":"3","author":"JR Beck","year":"1983","unstructured":"Beck JR, Pauker SG (1983) The Markov process in medical prognosis. Med Decis Mak 3:419\u2013458. https:\/\/doi.org\/10.1177\/0272989X8300300403","journal-title":"Med Decis Mak"},{"key":"9607_CR98","first-page":"18","volume":"80","author":"W Hopkins","year":"1988","unstructured":"Hopkins W (1988) Needle sharing and street behavior in response to AIDS in New York City. NIDA Res Monogr 80:18\u201327","journal-title":"NIDA Res Monogr"},{"key":"9607_CR99","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/j.1365-2893.2005.00643.x","volume":"12","author":"A Judd","year":"2005","unstructured":"Judd A, Hutchinson S, Wadd S et al (2005) Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis. J Viral Hepat 12:655\u2013662. https:\/\/doi.org\/10.1111\/j.1365-2893.2005.00643.x","journal-title":"J Viral Hepat"}],"container-title":["Health Care Management Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10729-022-09607-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10729-022-09607-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10729-022-09607-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T13:30:19Z","timestamp":1744205419000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10729-022-09607-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":99,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["9607"],"URL":"https:\/\/doi.org\/10.1007\/s10729-022-09607-2","relation":{},"ISSN":["1386-9620","1572-9389"],"issn-type":[{"value":"1386-9620","type":"print"},{"value":"1572-9389","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]},"assertion":[{"value":"20 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors confirmed no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests (include appropriate disclosures)"}}]}}